Clinical Trial Search

Primary: Difference Between the Anakinra Arm and Placebo Arm in Change in End-systolic Volume Indices From Baseline to Follow up Exam 10-14 Weeks Later at Cardiac Magnetic…

Primary: Adjusted Mean Monthly Percent of Days Covered With B-blocker Following Intervention Date — 66.37; 70.62 Adjusted monthly % of days covered

Primary: Major Adverse Cardiac and Cerebrovascular Events (MACCE) — 35.3; 13.8 Percentage of study group

Primary: Difference in Flow-mediated Dilation in the Brachial Artery in the Base and After the Treatment. — 11.24; 7.70 percent change dilatation — p=0.05

Primary: Change in Left Ventricular End Systolic Volume Index — -4.0; -2.0 ml/m^2 — p=0.19

Primary: Cardiac Death — 0; 0 events

Primary: Rate of Net Adverse Clinical Events (NACE) — 7; 0; 1; 1 Participants

Primary: High-Sensitivity Cardiac Troponin Levels From Days 0-7 — 29.2; 17.3; 23.2; 16.7 ng/mL (0-0.04) — p=0.05

Primary: Left Ventricular Global Strain Rate — 18; 23 percentage of change

Primary: Concentration of Platelet Extracellular Vesicles/ml — 2690000; 4310000 Platelet Extracellular Vesicles/mL

Primary: Prevalence of COPD in Patients Admitted to the Hospital With an Acute Myocardial Infarction (AMI) — 562 Participants

Primary: Average Peak Velocity (APV) Immediately Following Percutaneous Coronary Intervention (PCI) — 30; 19 cm/s — p=0.029

Primary: Myocardial Glucose Uptake. — 7.46; 7.22; 0.05; 20.89 umol/min/100g

Primary: Relative Reduction of 20% in Mean Anterior Myocardial Infarct Size as Determined by Cardiac Magnetic Resonance (cMR) Imaging at 4-6 Days Post Infarct in the Test Arm…

Primary: Quadriceps Strength — 2.1; 2.1; 2.8; 2.9 Nm/kg